Melanoma neoantigen vaccines: Are we getting more personal now?
- Resource Type
- Article
- Authors
- Latifyan, Sofiya; Haanen, John B.
- Source
- Med; April 2024, Vol. 5 Issue: 4 p288-290, 3p
- Subject
- Language
- ISSN
- 26666340
KEYNOTE-9421is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.